MDX2301
Phase 1Biologic
MDX2301 is one of 20 biologic programs targeting COVID-19. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Benadryl
PParkedale
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
MDX2301
MModeX Therapeutics, An OPKO Health Company
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MDX2301. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details